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Abstract:  41 
Rationale: DNA-based microbiological studies are moving beyond studying healthy human microbiota to 42 
investigate diverse infectious diseases, including chronic respiratory infections such as those in the airways of 43 
people with cystic fibrosis (CF) and non-CF bronchiectasis (BE).  The species identified in the respiratory 44 
secretion microbiota from such patients can be classified into those that are common and abundant among 45 
similar subjects (core) versus those that are infrequent and rare (satellite).  This categorization provides a vital 46 
foundation for investigating disease pathogenesis and improving therapy.  However, whether the core microbiota 47 
of people with different respiratory diseases, which are traditionally associated with specific culturable 48 
pathogens, are unique or shared with other chronic infections of the lower airways is not well studied. Little is 49 
also known about how these chronic infection microbiota change from childhood into adulthood. 50 
 51 
Objectives: We sought to compare the core microbiota in respiratory specimens from children and adults with 52 
different chronic lung infections. 53 
 54 
Methods: We used bacterial 16S rRNA gene pyrosequencing, phylogenetic analysis, and ecological statistical 55 
tools to compare the core microbiota in respiratory samples from three cohorts of symptomatic children with 56 
clinically distinct airway diseases (protracted bacterial bronchitis, BE, CF), and four healthy children. We then 57 
compared the core pediatric respiratory microbiota with those in samples from adults with BE and CF.  58 
 59 
Measurements and Main Results: All three pediatric disease cohorts shared strikingly similar core respiratory 60 
microbiota that differed from adult CF and BE microbiota. The most common species in pediatric disease cohort 61 
samples were also detected in those from healthy children. The adult CF and BE microbiota also differed from 62 
each other, suggesting common early infection airway microbiota that diverge by adulthood. The shared core 63 
pediatric microbiota included both traditional pathogens and many species not routinely identified by standard 64 
culture.  65 
 66 
Conclusions: Our results indicate that these clinically distinct chronic airway infections share common early 67 
core microbiota, which are likely shaped by natural aspiration and impaired clearance of the same airway 68 
microbes, but that disease-specific characteristics select for divergent microbiota by adulthood. Longitudinal and 69 
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interventional studies will be required to define the relationships between microbiota, treatments, and disease 70 
progression. 71 
 72 
Number of words in this abstract: 349 73 
 74 
75 
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Introduction 76 
A growing body of evidence indicates that the airways of even healthy people contain detectable 77 
microbes (1–4), and that these microbiota are altered in many chronic lung diseases. For example, culture-78 
independent analyses of cystic fibrosis (CF) respiratory samples have revealed remarkably diverse microbial 79 
communities compared with culture results. Among the bacteria detected most frequently, and at highest 80 
abundance, in those CF samples were anaerobic species not usually detected by standard laboratory methods 81 
(5). Both cross-sectional and longitudinal studies indicate that CF airway microbiota generally decrease in 82 
diversity over time, concurrent with a decrease in average lung function (6–9). Whether these ecological 83 
changes are the cause of lung function decline, or whether they are the result of increasing antibiotic exposure 84 
or changing properties of the infected airways, are not understood (9). Furthermore, exactly where the species 85 
that comprise CF secretion microbiota come from, and whether features unique to the CF airway or its 86 
secretions select for CF-specific microbiota, are unknown. 87 
Several other childhood lung diseases also involve chronic airway infection, including non-CF 88 
bronchiectasis (BE) and protracted bacterial bronchitis (PBB) (10). At least some underlying factors that 89 
predispose to infection in CF, BE, and PBB may be shared (e.g., mucus hypersecretion or stasis, impaired 90 
airway clearance), while others vary (e.g., inflammatory response, intensity of antibiotic use, physicochemical 91 
mucus characteristics), and the associated infectious microbiota could therefore differ at the beginning or 92 
throughout these diseases. In support of this concept, specific microbes have been associated with the 93 
pathogenesis of each of these diseases in culture-based studies. For example, Staphylococcus aureus and 94 
Pseudomonas aeruginosa are traditionally associated with CF lung disease (11). In contrast, Streptococcus 95 
pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae are traditionally associated with both PBB and 96 
early BE (10), with P. aeruginosa associated with more advanced BE disease (12). Treatment regimens 97 
therefore tend to differ for each disease, designed to target specific pathogens. Moreover, it has been suggested 98 
that these bacteria play primary roles in initiating or driving associated symptoms (13), which could imply 99 
disease-specific infection pathogenesis. However, it is now known that children with CF have lung disease 100 
without detectable infection by P. aeruginosa or S. aureus (14, 15). The identification of diverse microbiota in 101 
even healthy airways further complicates the task of delineating “infected” and/or “pathogenic” from “normal” 102 
conditions. Therefore, comparing the earliest stages of chronic infection for diverse airways diseases could be 103 
helpful in understanding whether infection begins (and drives disease) in distinct or similar ways in different 104 
conditions.  105 
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An analytical approach that has been particularly useful in understanding environmental and infectious 106 
microbiota involves partitioning the constituent microbes into core and satellite species (7). In cross-sectional 107 
studies, core species are those that are detected in the majority of samples from subjects with a specific 108 
disease, while satellite species are those that are infrequent. While this categorization does not necessarily 109 
identify which species are pathogens, it provides a useful framework within which to compare microbiota from 110 
different subject groups, and the resulting similarities and differences have important implications for infection 111 
pathogenesis. Here, we compared the core and satellite microbiota in three very different cohorts of children with 112 
PBB, BE, and CF using next-generation sequencing and ecological analytical approaches. Because these study 113 
subjects were children, and therefore at relatively early stages of disease, we hypothesized that these cohorts 114 
would have similar, rather than disease-specific, early core respiratory sample microbiota. We then compared 115 
pediatric and adult CF and BE respiratory metacommunities, using data from two of our recent adult studies (16, 116 
17) to identify evidence of disease-specific changes in microbiota as patients with each disease progress to 117 
adulthood. 118 
 119 
120 
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Materials and methods 121 
Patients and clinical samples  122 
All children in this study were participants in previous studies of CF, PBB, and BE, respectively (18–20). 123 
Inclusion and exclusion criteria and study details are listed in the Online Supplement. Sputum and 124 
bronchoalveolar lavage (BAL) fluid, as well as clinical data, were collected during those studies as described 125 
(18–20). The study was approved by the institutional review boards at Seattle Children’s Hospital (SCH) for the 126 
CF samples, and at the Royal Children’s Hospital (RCH, Brisbane, Australia) for the PBB, BE and control 127 
pediatric samples. Data from two adult BE (n = 38 samples, age 37 - 74 years) and CF (n = 30, 18 - 55 years) 128 
cohorts from previous studies were used for metacommunity comparisons with the microbiota from the pediatric 129 
cohorts (16, 17). 130 
 131 
DNA extraction and Q-PCR 132 
Full details of DNA extraction from BAL and sputum samples, and of the use of quantitative PCR to 133 
determine total bacterial abundance using universal eubacterial primers, are in the Online Supplement.  134 
   135 
Bacterial Tag-Encoded FLX Amplicon Pyrosequencing (bTEFAP) and sequence analyses 136 
The bacterial taxonomy of each sample was evaluated using bacterial tag-encoded FLX-titanium 137 
pyrosequencing (bTEFAP) of a fragment of the 16S rRNA gene covering the V1-V3 variable regions, as 138 
described previously (21). Details of amplification, sequencing, and sequence processing and analysis are in the 139 
Online Supplement. 140 
 141 
Statistical analyses 142 
To avoid potential biases in comparisons of diversity between local communities due to varying number 143 
of sequences per sample, a randomised re-sampling method, using three indices of diversity (S*, H’, and 1-D), 144 
were employed as previously described (7).  Bacterial species within each metacommunity were partitioned into 145 
core and satellite species groups using the Poisson distribution test as previously described (7) (Online 146 
Supplement). 147 
148 
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Results 149 
Pediatric study cohorts 150 
We analysed the microbiota in respiratory samples (sputum and BAL fluid) from 3 cohorts of children 151 
with BE, PBB, and CF, respectively. All of these children either underwent bronchoscopy for chronic wet cough 152 
or were expectorating, indicative of symptomatic disease. As shown in Table 1, the cohorts were substantially 153 
different in terms of demographic and treatment features that could play important roles in determining the 154 
airway microbiota, including age, antibiotic exposure, and P. aeruginosa culture-positivity, which have each been 155 
shown to correlate inversely with airway microbiota diversity in CF, and FEV1% predicted, which correlates 156 
directly with diversity (9). The children with CF also had higher rates of inhaled corticosteroid use, a treatment 157 
that could conceivably alter airway microbiota constituency (2). The CF cohort originated entirely from a single 158 
hospital in the US, whereas all children with BE and PBB were from a single hospital in Australia. Each of these 159 
differences, if they were to influence airway microbiota, would be unlikely to bias our analyses towards finding 160 
microbial similarities between the three cohorts. 161 
 162 
Pediatric community diversity and composition 163 
Bacterial pyrosequencing data were used to assess and compare diversity and composition of 164 
microbiota from respiratory samples within and across the 3 pediatric cohorts.  A total of 408,335 bacterial 165 
sequence reads (mean ± SD per sample, 5041 ± 3557), identifying 104 genera and 225 distinct operational 166 
taxonomic units (OTUs) classified to species level (Table S1), were generated from all samples combined. The 167 
average numbers of bacterial sequence reads per sample were similar among the three cohorts (mean ± SD: 168 
BE, 4284 ± 3476; PBB, 4471 ± 3718; and CF, 4785 ± 2702). Estimates of total bacterial abundances were also 169 
similar when quantified by qPCR (for all samples, including sputum and BAL cell pellets, from which sufficient 170 
DNA remained after sequencing analysis, mean cfu/mL equivalents/sample ± SD: BE, 1.47 x10
7 
± 2.32 x10
7
 171 
N=18 samples; PBB, 9.89 x10
6
 ± 1.38 x10
7
, N=10; and CF, 5.82 x10
7
 ± 6.28 x10
7
, N=21).  172 
Bacterial diversity within and between cohorts was compared using three indices of diversity: species 173 
richness (S*, the total number of species), Shannon-Wiener (H’, a metric that accounts for both number and 174 
relative abundance of species), and Simpson’s (1-D, a measure of the probability that two species randomly 175 
selected from a sample will differ). Bacterial diversity between BE sputum and BAL samples was compared 176 
using all three measures and found not to be significantly different (P > 0.05, Fig. S1), and hence those samples 177 
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were combined for subsequent analyses. S* was found to vary substantially within cohorts, with means of 30.6 ± 178 
10.5, 30.9 ± 11.5, and 19.5 ± 10.0 for the BE, PBB, and CF cohorts, respectively (Fig. 1); similar results were 179 
obtained for H’ and 1-D (Fig. 1 and Table S2).  Diversity between pediatric cohorts was not significantly different 180 
(P > 0.05) in all instances except for one measure (H’) between the PBB and CF cohorts (Table S2). 181 
Similarities and differences in community membership and structure for microbiota samples both within 182 
and between disease cohorts were assayed with two different indices: Sørensen (SSOR, which accounts for the 183 
number of species present in each community and those that are shared) and Bray-Curtis quantitative (SBC, 184 
similar to SSOR but also accounts for abundance of each species). Each index varies in value from 0 to 1, with 185 
higher values indicating greater similarity. It has been previously observed that community composition is highly 186 
variable between CF patients (7, 22). Here, we found that observation held regardless of underlying pediatric 187 
lung disease, with mean similarities in bacterial community membership taken pair-wise for samples within 188 
pediatric cohorts of SSOR = 0.44 ± 0.14 for BE (n = 171 pair wise comparisons); SSOR = 0.51 ± 0.12 for PBB (n = 189 
66); and SSOR = 0.50 ± 0.12 for CF (n = 300), with a mean similarity of the entire pool of samples of SSOR = 0.46 ± 190 
0.13 (n = 1540) (Fig. 2). For SBC, the mean between all samples was SBC = 0.19 ± 0.15 (n = 1540), while that 191 
within cohorts was SBC = 0.18 ± 0.14 for BE (n = 171); SBC = 0.27 ± 0.12 for PBB (n = 66); and SBC = 0.27 ± 0.17 192 
for CF (n = 300). Therefore, individual sample microbiota differed within each pediatric disease group to a similar 193 
degree, and the microbiota identified within each pediatric cohort’s samples were pooled together into disease-194 
specific metacommunities (defined as the set of all microbiota identified in samples from a given cohort) for 195 
subsequent comparisons. 196 
 197 
Microbiota within a metacommunity framework 198 
Previously, we established that the categorization of component species in CF microbiota into core and 199 
satellite species revealed important aspects of species-abundance distributions within a metacommunity that 200 
would be neglected without such a distinction (7).  A coherent metacommunity could be expected to exhibit a 201 
direct relationship between prevalence and abundance of individual species within the constituent communities. 202 
Consistent with this prediction, the abundance of species in each pediatric study cohort was significantly 203 
correlated with the number of individual respiratory sample communities those species occupied (Fig. 3A). 204 
The species identified in each pediatric cohort metacommunity were then classified as core or satellite 205 
based upon their distributions (Fig. 3B). Of the 177 species that comprised the BE metacommunity, 88 were core 206 
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and 89 were satellite species. The PBB metacommunity (130 species) was comprised of 63 core and 67 satellite 207 
species, and the CF metacommunity (143 species) comprised of 66 and 77 species, respectively. 208 
Similarities between the three pediatric metacommunities were assayed using SSOR and SBC indices for 209 
all species, and for the core and satellite groups. The resulting cluster analysis revealed community membership 210 
to be relatively well-conserved between cohorts for all species (SSOR = 0.74 ± 0.02 [n = 3 pair-wise 211 
comparisons]), but much more highly conserved between the core groups (SSOR = 0.93 ± 0.02) (Fig. 4).  The 212 
satellite groups, comprised of randomly distributed species, were highly divergent (SSOR = 0.35 ± 0.01).  Results 213 
from Bray-Curtis quantitative analyses were similar: All SBC = 0.50 ± 0.10; core SBC = 0.51 ± 0.10; and satellite 214 
SBC = 0.10 ± 0.02. These results indicate that the high level of similarity between the three pediatric cohort 215 
metacommunities is attributable to core species. 216 
To determine whether disease-specific microbiota emerge with disease progression into adulthood for 217 
the two chronic diseases, BE and CF (PBB usually improves long-term with antibiotic treatment (10)), we 218 
compared the microbiota from our previous studies of adult CF (16) and BE (17) cohorts with the pediatric cohort 219 
microbiota. The adult BE cohort metacommunity (n = 38 patients) was comprised of 86 core and 54 satellite 220 
species, while the adult CF cohort (n = 30) metacommunity was comprised of 68 core and 81 satellite species. 221 
The resulting analyses revealed adult community membership to be highly divergent in all cases (whole 222 
microbiota SSOR = 0.36 ± 0.03; core SSOR = 0.46 ± 0.06; and satellite SSOR = 0.09 ± 0.03 [n = 6 pairwise 223 
comparisons in all cases]) (Fig. 4).  When relative abundances of constituent taxa were included to examine 224 
differences in community structure, an even more pronounced divergence was observed than for membership 225 
(whole SBC = 0.07 ± 0.03; core SBC = 0.07 ± 0.04; and satellite SBC = 0.01 ± 0.01 [n = 6 in all cases]).  In addition, 226 
comparisons between the adult CF and BE metacommunities also revealed a high degree of divergence both in 227 
terms of membership (whole SSOR = 0.38; core SSOR = 0.48; and satellite SSOR = 0.16) (Fig. 4) and structure 228 
(whole SBC = 0.05; core SBC = 0.05; and satellite SBC = 0.02).  Therefore, the adult CF and BE microbiota differed 229 
substantially from each other, contrasting with the similarities among the pediatric cohort microbiota.  230 
To test whether the adult and pediatric metacommunities were significantly similar or dissimilar, the 231 
whole, core, and satellite microbiota were compared between cohorts using the Raup and Crick probability-232 
based similarity index (SRC) to determine whether compositional similarities in the microbiota were more or less 233 
significantly similar than expected by chance (Fig. 5). The resulting cluster analysis revealed the pediatric whole, 234 
core, and satellite microbiota to be significantly dissimilar (SRC < 0.05) from the corresponding adult CF and BE 235 
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microbiota.  Likewise, the whole and core microbiota from the pediatric cohorts were significantly similar (SRC > 236 
0.95), adding further weight to the observations of pediatric community membership (SSOR) and structure (SBC) 237 
(Fig. 5).  In contrast, the pediatric satellite microbiota were not significantly similar or dissimilar to each other 238 
(SRC > 0.05 and < 0.95), which would be expected given that satellite microbiota in a given cohort represent rare 239 
and randomly distributed species.  Furthermore, the adult CF and BE microbiota were significantly dissimilar to 240 
each other (SRC < 0.05) (Fig. 5).   241 
Similarity of percentages (SIMPER) analysis of the metacommunities was used to identify those species 242 
that contributed most to the observed similarity between the three pediatric cohorts. These species, all core 243 
group members, are listed in decreasing order of contribution in Table 2. H. influenzae contributed the greatest 244 
amount to the observed similarity between pediatric samples. Most of the major contributors have previously 245 
been associated with respiratory tract infections and other opportunistic infections, and many are known 246 
inhabitants of the oral cavity, including both aerobic and anaerobic species (Table S1). These findings 247 
contrasted with the SIMPER analysis of the adult CF cohort, wherein P. aeruginosa contributed over 83% to the 248 
observed similarity between samples (Table S3a) in addition to 3 other species: Streptococcus pneumoniae, 249 
Prevotella melaninogenica, and Veillonella parvula.  Within the adult BE cohort, the main contributors to the 250 
overall similarity between samples were H. influenzae (50.4%), P. aeruginosa (8.62 %) and V. dispar (8.11%) 251 
(Table S3b) along with S. pneumoniae and, as for the pediatric cohorts, other species associated with 252 
respiratory infections, many of which are known oral microbiota members.  As also observed for the pediatric 253 
cohorts, the species identified from the SIMPER analyses for both adult cohorts were all core species in their 254 
respective metacommunities. Although there were some species identified in common for the adult and pediatric 255 
cohorts by the SIMPER analyses, these similarities were greatly outweighed by the differences in species 256 
content, accounting for the observed differences in whole and core microbiota within each adult-pediatric 257 
disease cohort pair. 258 
To investigate whether the core microbiota shared between the three pediatric disease groups were 259 
unique to children with airways disease, we identified the microbiota in BALF from four children who underwent 260 
bronchoscopy for reasons other than suspected infection (described in the Online Supplement and 
16
). Of the 10 261 
shared core species that contributed the most to similarity between disease cohorts from Table 2, six were 262 
detected in all four “control” samples, and the other four species were detected in three of the four samples, 263 
suggesting that the shared core microbiota are commonly found in healthy, as well as diseased, children’s 264 
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airways (Table S4), consistent with prior airway microbiota studies that included samples from healthy 265 
subjects
3,21
. 266 
267 
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Discussion 268 
We found that cohorts of symptomatic children with three clinically distinct airways diseases- CF, BE, 269 
and PBB- shared remarkably similar respiratory sample core microbiota, the most common of which were also 270 
found in airway samples from children without clinical evidence of infection. The shared core microbiota included 271 
both traditional pathogens and many bacteria that are either not identified by routine clinical laboratory methods 272 
or are generally classified as “oral flora” and are routinely ignored with respect to pathophysiology or treatment. 273 
In contrast, the respiratory sample microbiota from adults with CF and BE differed significantly from each other 274 
and from those of children with the same disease. These results indicate that the core microbes in different 275 
chronic respiratory infection types likely begin similarly, yet are divergent by adulthood. 276 
While these observations provide valuable insight into the microbiota in diseased airways, they also 277 
identify next steps to take in understanding the pathogenesis of diverse airway infections. Given the high 278 
abundance and prevalence of the core species among pediatric patients, one interpretation of these results 279 
could be that the core species represent those that contribute the most to airway inflammation and disease 280 
progression. Alternatively, it could be that the satellite species play key pathogenic roles in specific contexts or 281 
stages of infection; for example, infection at any stage with specific low-abundance or infrequent bacteria could 282 
lead to increased inflammation, airway damage, mucus hypersecretion, and/or clinical deterioration. While these 283 
questions are not fully answered by the current study, the relative rarity of any specific species in each satellite 284 
group may indicate a consistent, general role for the core groups in pathogenesis. Future studies will be required 285 
to longitudinally compare the changes over time in airway microbiota in health and disease to better understand 286 
the microbial contribution to pathogenesis, and the best therapeutic approach to infection. 287 
These findings provide valuable perspective for results from studies of many respiratory diseases, 288 
usually at more advanced stages (2). A study using a relatively low-depth sequencing technique, 16S rRNA 289 
gene clone sequencing, comparing microbiota in explanted lungs from adults with end-stage BE and CF 290 
identified diverse communities often dominated by Pseudomonas in both sample sets (23). Likewise, two studies 291 
using the same technique applied to sputa from patients with CF and BE found some similarities and some 292 
differences between the subject groups, but no formal comparisons were made (24, 25). In support of our results 293 
(17), a recent pyrosequencing study of 21 older adults with non-CF bronchiectasis showed their sputum to 294 
contain diverse microbiota (26). Studies of sputum, BAL fluid, and explanted lung tissue from patients at various 295 
stages of disease due to chronic obstructive pulmonary disease (COPD) and asthma, sometimes comparing with 296 
14 
 
healthy subjects, have yielded varying and often conflicting results, in some cases demonstrating disease-297 
specific microbiota and in others identifying substantial overlap (1, 2, 27–29). In all of these studies, the effects 298 
of therapies that could conceivably impact airway microbiota, such as intubation, steroids and antibiotics, were 299 
difficult to control for. Our results suggest that the microbiota observed in those older patients, at later stages of 300 
disease, likely had similar (or identical) beginnings and diverged over time. Whether those changes resulted 301 
from features of the underlying disease or from differences in treatment are not yet clear. While the differences in 302 
antibiotic use among study cohorts support the idea that antibiotics did not have a profound, lasting impact on 303 
airway microbiota (similar to observations from CF (8, 30)), and there was no evidence that differences in steroid 304 
use resulted in differences in microbiota in these children, chronic or repetitive drug exposure could have 305 
gradual effects (as indicated by longitudinal studies in CF (9)). Regardless, these findings suggest that factors 306 
intrinsic to airways predominate in establishing the early microbiota in these chronic respiratory infections. 307 
Several observations support these conclusions. Culture-based studies of children with CF 308 
demonstrated that radiographic lung disease, respiratory symptoms, and inflammation all precede the detection 309 
of “standard CF pathogens” (14, 15, 31, 32). All of the shared core microbes identified in the current study, many 310 
of which would traditionally be considered “oral flora”, were also commonly identified in oropharyngeal swabs 311 
from infants with CF by pyrosequencing (33). The identification of such “oral flora” has been associated with both 312 
inflammation (32) and structural lung disease (15) in children with CF. Similarly, piglets with engineered CFTR 313 
mutations (34) concurrently develop diverse airway microbiota and lung disease similar to those observed in 314 
children with CF. The cultured microbiota of CF pigs were similar in constituency to those of wild-type pigs, but 315 
more persistent and higher in abundance. Therefore, the requirement for traditional pathogens for CF lung 316 
disease or symptom development is questionable.  317 
Both cross-sectional and longitudinal studies of CF respiratory samples using molecular methods have 318 
demonstrated correlations between decreasing microbiota diversity, age, and disease progression (3, 8, 9, 30). 319 
Interestingly, some organisms traditionally associated with chronic airways disease were classified as core 320 
species in some disease cohorts but not others in our study (for example, P. aeruginosa, S. aureus, and several 321 
species each of Veillonella and Prevotella were core members in both the CF and BE metacommunities, but 322 
satellite for PBB, Table S1). Collectively, these results could indicate that particular microbes are associated with 323 
and/or accelerate specific lung diseases. Alternatively, changes over time in airway microbiota, including the 324 
gradual decrease in community diversity observed in CF and in COPD (28), and the gradual identification of P. 325 
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aeruginosa in people with CF and non-CF bronchiectasis (23), could all result from intensified antibiotic 326 
treatment and/or underlying disease, but this concept would not require the microbes that eventually dominate to 327 
be particularly pathogenic. Similarly, changes in the respiratory microbiota could result from evolution (therapy-328 
driven or otherwise) in another reservoir that seeds the airways, such as the oropharynx (as suggested by 329 
abundance in our study of microbes traditionally associated with this space (35)) or the GI tract (which a recent 330 
longitudinal study of infants with CF suggested could be a source for respiratory microbiota (33)).  331 
Together with the above earlier studies, our results support a unified model of early airway infections, in 332 
which a defect in the clearance of otherwise normal airway microbiota (for example, due to early airway injury, 333 
altered mucus, defective ciliary motility, mechanical obstruction, or immunodeficiency) contributes to progressive 334 
inflammation and airway damage. In this model, an extension of the “vicious cycle hypothesis” (13), either 335 
medical treatment or the physical effects of underlying disease (such as diseased tissue or accumulated 336 
secretions) could lead to progressive change in the microbiota. These microbiological changes (including 337 
eventual selection for P. aeruginosa in CF or BE) could in turn accelerate lung disease, or they could be 338 
consequences rather than causes of this progression. Future studies, either interventional or longitudinal, may 339 
be able to refine this model. 340 
Antibiotics play important roles in the management of all three of these symptomatic chronic infections. 341 
For example, inhaled and oral antibiotics are commonly used in CF and BE both for maintenance (11, 36) and 342 
exacerbation treatments (11, 13). For PBB, a prolonged course of antibiotics usually leads to resolution of 343 
symptoms (18). These observations underscore the importance of bacteria in the pathogenesis of each disease; 344 
the current findings provide a rationale for reexamining and comparing the culture-based antibiotic approaches 345 
to each of these airway infections, particularly during early stages. 346 
Our study was limited by the small sizes of each subject group. The groups were not matched for age, 347 
treatment, disease severity, or demographics, limiting our ability to determine relationships between microbiota 348 
and these factors. However, the similarity in microbiota among demographically and clinically divergent pediatric 349 
groups could be interpreted to further support the concept of a common early pediatric respiratory microbiota; 350 
additional study with demographically well-matched cohorts could strengthen this argument. We did not 351 
distinguish between viable and nonviable cells in the current analysis due to the small volumes of many of the 352 
samples analyzed, and thus the detection of a microbe cannot definitively be said to indicate its persistence 353 
(although even transient or nonviable bacterial cells could potentially contribute to airway inflammation). 354 
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Similarly, it could be proposed that the microbial diversity found in our study and others is due to contamination 355 
by upper airway bacteria during sample collection. However, the significant similarity in microbiota among 356 
sputum and BAL samples from the children with BE in our study, as observed in studies of children with CF (5, 357 
22), as well as the high abundance of microbes in our samples, argue against this issue significantly altering our 358 
findings.  359 
In conclusion, children with early chronic lung infections due to three distinct diseases shared strikingly 360 
similar core airway microbiota that included many bacteria not generally identified by clinical laboratory culture. 361 
These similarities were independent of underlying diagnosis or disease severity, geography, antibiotic and 362 
steroid use, and age. These results indicate that different chronic airway infections begin similarly, remaining 363 
similar even after symptoms have begun, but diverging by adulthood. Our findings provide a baseline to 364 
compare with in future, longitudinal microbiota studies of diverse chronic airway infections, which would provide 365 
vital insight into the microbial determinants of chronic lung disease progression and could lead to improved 366 
treatments. 367 
368 
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 493 
Figure legends 494 
Fig. 1. Box plot comparisons of bacterial diversity between the BE, PBB, and CF cohorts. Given are three 495 
measures of diversity: species richness (S*), Simpson’s complement index (1-D), and Shannon-Wiener index 496 
(H’). The top and bottom boundaries of each box indicate the 75
th
 and 25
th
 quartile values, respectively, and lines 497 
within each box represent the 50
th
 quartile (median) values. Ends of whiskers mark the lowest and highest 498 
diversity values in each instance. One-way ANOVA summary statistics are given in Table S2. The only 499 
significant difference found was for H’ between the CF and PBB cohorts (P=0.027, Table S2). 500 
 501 
Fig. 2. Dendrograms of bacterial community membership for all patients from the BE, PBB, and CF cohorts. 502 
Black, grey, and white shaded boxes are given to show positions of BE, PBB, and CF samples, respectively. 503 
Patient species profiles were compared using the Sørensen index of similarity and un-weighted pair-group 504 
averages (UPGMA). 505 
  506 
Fig. 3. Distribution and dispersal of bacterial species among BE, PBB, and CF pediatric cohorts. (A) The number 507 
of samples for which each detected bacterial species (open circles) was observed, plotted against the 508 
abundance (log10 scale) of that species among all samples within each cohort (BE, r
2
 = 0.64, F1,175 = 311.5, P < 509 
0.0001; PBB, r
2
 = 0.72, F1,128 = 321.1, P < 0.0001; and CF, r
2
 = 0.75, F1,141 = 418.4, P < 0.0001). (B) A dispersal 510 
plot to identify which bacterial species are randomly distributed within each cohort, a measure used to assign 511 
core versus satellite status. Index of dispersion was calculated as the ratio of variance to mean of abundance for 512 
each species within each cohort and plotted for each sample. The line depicts the 2.5 % confidence limit for the 513 
χ
2
 distribution. Species that fall below this line are randomly distributed and were considered satellite species, 514 
whereas those that are above the line are non-randomly distributed and were considered core species. The 97.5 515 
% confidence limit was not plotted, as no species fell below that line. 516 
 517 
Fig. 4. Dendrograms of community membership similarity between the pediatric BE, PBB, and CF bacterial 518 
metacommunities and compared with adult CF and BE metacommunities. Given are whole, core and satellite 519 
microbiota. Metacommunity profiles were compared using the Sørensen index of similarity and UPGMA. 520 
Similarities between the microbiota from different cohorts are read as the location of the horizontal line 521 
23 
 
connecting those cohorts (the “node”) on the Y-axis; for example, the similarity between pediatric core microbiota 522 
was ≥ 90%, while that between adult core microbiota was ≥ 40%. 523 
 524 
Fig. 5. Dendrograms of Raup and Crick (SRC) probability-based index of similarity between the pediatric BE, 525 
PBB, and CF bacterial metacommunities and compared with adult CF and BE metacommunities.  Given are the 526 
whole, core and satellite microbiota. SRC < 0.95 and SRC > 0.05 denote similarity no greater than expected by 527 
chance. SRC < 0.05 denotes significant dissimilarity and SRC > 0.95 significant similarity.  The 0.05 and 0.95 528 
thresholds are depicted with dashed lines in each instance. Dendrograms were constructed using UPGMA. 529 
 530 
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Tables: 532 
Table 1. Demographic characteristics of the pediatric study groups. 533 
 534 
Clinical Characteristic BE
1 
PBB CF 
Number of subjects 19 12 25 
Geographic origin Australia (Brisbane) Australia (Brisbane) US (Seattle) 
Sample type 9 BAL & 10 Sputum All BAL All Sputum 
Age (y; Mean ± SD, range) 8.9± 4.7, 1.8-16.3
6 
2.3 ± 1.7, 0.6-5.5
4, 5 
12.5±3.5, 2.3-17.7 
Gender (% female) 36% 25% 68% 
FEV1 % predicted (Mean ± 
SD, range, no. subjects 
with measurements) 
85.7 ± 21%, 41-120%, 15 
subjects 
117 ± 1.4%, 116 and 
118%, 2 subjects
4, 5 
77.9 ± 24%, 22.2-
116.2%, 21 subjects 
Number (%) of subjects on 
antibiotics at sampling
2 
8 of 19 (42%) 1 of 12 (8%) 7 of 25 (28%) 
Number (%) of subjects on 
corticosteroids at sampling 
6 of 19 (32%), one oral, 5 
inhaled 
2 of 12 (16%), all inhaled 11 of 25 (48%), all 
inhaled 
Number (%) culture-
positive for P. aeruginosa
3 
0 0 8 (34%) 
Number (%) culture-
positive for S. aureus
3 
2 (11%) 2 (16%) 22 (96%) 
Number (%) culture-
positive for H. influenzae
3
 
4 (19%) 6 (50%) 7 (30%) 
 535 
1 
Of the 10 children with BE with additional diagnoses available, 5/10 (50%) had idiopathic bronchiectasis, one 536 
had previously had an airway foreign body, one had primary ciliary dyskinesia, one had chronic aspiration due to 537 
a tracheoesophageal fistula, one had Mounier-Kuhn syndrome, and one had common variable 538 
immunodeficiency. 539 
2 
Antibiotics for children with CF included tobramycin (inhaled), linezolid, levofloxacin, ciprofloxacin, trimethoprim-540 
sulfamethoxazole, ticarcillin-clavulanate, and amoxicillin-clavulanate. Antibiotics for children with PBB included 541 
only erythromycin. Antibiotics for children with BE included erythromycin, azithromycin, roxithromycin, 542 
clarithromycin, amoxicillin-clavulanate, cefotaxime, ceftriaxone, and ticarcillin-clavulanate. 543 
3 
Of 23 subjects with CF with culture data available; all subjects with PBB and BE had available culture data. 544 
4
 P < 0.001 compared with CF; 
5
 P < 0.001 compared with BE; 
6
 P < 0.01 compared with CF. 545 
546 
25 
 
Table 2. Similarity of Percentages (SIMPER) analysis of bacterial community similarity (Bray-Curtis) between 547 
pediatric metacommunities. Given is occupancy, or the number of patients for each disease group a given 548 
species was detected in. Next is mean % abundance of sequences for a species across the samples it was 549 
observed to occupy. Mean contribution represents the average contribution of a given species to the average 550 
similarity between samples (overall mean = 50.2%). Percentage contribution is the mean contribution divided by 551 
mean similarity across samples. The list of species is not exhaustive, so cumulative % value does not sum to 552 
100%. Species level identities of detected taxa are reported here. However, given the length of the ribosomal 553 
sequences analysed, these identities should be considered putative. 554 
 555 
 
Occupancy
1 
    Species BE PBB CF Mean Abund. Mean Cont. % Cont. Cum. % 
Haemophilus influenzae 12 11 19 23.22 18.79 37.44 37.44 
Streptococcus mitis 18 12 25 14.59 8.45 16.84 54.28 
Prevotella melaninogenica 16 11 24 9.16 4.59 9.15 63.43 
Veillonella dispar 19 12 24 4.48 3.90 7.77 71.20 
Fusobacterium nucleatum 17 11 21 2.63 1.99 3.97 75.17 
Neisseria flavescens 12 11 19 5.04 1.73 3.44 78.61 
Porphyromonas catoniae 17 11 18 1.66 1.05 2.09 80.70 
Haemophilus parainfluenzae 15 10 16 1.30 1.04 2.06 82.76 
Porphyromonas gingivalis 17 9 17 1.60 0.97 1.92 84.69 
Prevotella nanceiensis 13 11 15 0.85 0.54 1.08 85.77 
Prevotella histicola 12 7 19 0.81 0.46 0.92 86.69 
Granulicatella adiacens 15 10 19 0.53 0.44 0.87 87.57 
Prevotella oris 10 4 13 1.07 0.37 0.73 88.30 
Sphingomonas echinoides 9 7 3 0.73 0.36 0.71 89.02 
Gemella morbillorum 13 11 21 0.86 0.35 0.70 89.71 
Prevotella pallens 16 8 13 0.63 0.32 0.63 90.35 
1
Total N for each pediatric disease cohort: BE, 19; PBB, 12; CF, 25. 556 
557 
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Figure 5 627 
 628 
 629 
